Glenmark Pharmaceuticals Ltd (NSE:GLENMARK)
₹ 1194.15 -15.7 (-1.3%) Market Cap: 336.71 Bil Enterprise Value: 330.69 Bil PE Ratio: 0 PB Ratio: 4.29 GF Score: 83/100

Q3 2021 Glenmark Pharmaceuticals Ltd Earnings Call Transcript

Feb 15, 2021 / 03:00AM GMT
Release Date Price: ₹490.65 (-2.67%)
Operator

Ladies and gentlemen, good day, and welcome to the Q3 FY '21 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) There will be an opportunity for you to ask questions after the presentation concludes. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Jason D'souza. Thank you, and over to you, sir.

Jason D;souza
Glenmark Pharmaceuticals Limited - Senior VP & Head of Corporate Strategy

' -

Thank you, moderator. Welcome to Glenmark's Q3 earnings call.

Before we start the call, the review of operations for the quarter ended December 31, 2020. For the third quarter of FY '21, Glenmark's consolidated revenue was at INR 27,867 million, recording an increase of 1.87%. For the third quarter, Glenmark consolidated sales was at INR 27,605 million, recording an increase of 3.88%. For the 9 months ended December 31, Glenmark's consolidated revenue was INR 80,840 million, recording an increase of 2.67%.

Glenmark issued $200 million,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot